Listing timing unconfirmed
Last verified 9 Oct 2026The previously expected date of 9 Oct 2026 has passed. Trading has not been confirmed.
- IPO valuation
- $100MBasic equity value after the offering
- IPO price
- $12.00Per share · USD
- Offering size
- $45MBase offering, before overallotment
- Previously expected
- 9 Oct 2026Listing timing unconfirmed
Company overview
Retension Pharmaceuticals websiteRetension Pharmaceuticals is a clinical-stage biopharmaceutical company. It focuses on developing medicines to treat hypertension and other cardiovascular diseases.
- Company country
- United States
Offering details
USD · Base offering, before overallotment
- Exchange
- Nasdaq Capital Market
- Ticker
- RTSN
- Shares offered
- 3,750,000
- Shares after offering
- 8,331,599
Valuation and offering basis
Basic equity valuation is the price per share multiplied by all shares outstanding immediately after the offering. It is different from enterprise value or fully diluted valuation. Offering size and gross proceeds exclude optional additional shares, fees and expenses. Ranges use the proposed price range; figures are rounded.
IPO timeline
- Registration filed
- Proposed terms published
- Proposed terms published
- Proposed terms published
- Proposed terms published
- Final offer price announcedRetension Pharmaceuticals prices its IPO
- Final offer price announcedRetension Pharmaceuticals prices its IPO
- Final offer price announcedRetension Pharmaceuticals prices its IPO
- Proposed terms published
- Proposed terms published
- Previously expected first trading day · Announced date
Filings and documents
- Pricing announcementChecked 9 Oct 2026 (undated source)View document
- Pricing announcementChecked 9 Oct 2026 (undated source)View document
- View document
- View document
- View document
- Updated offering termsChecked 6 Oct 2026 (undated source)View document
- View document
- Updated offering termsChecked 5 Oct 2026 (undated source)View document
- View document
- View document